Biologic drugs for psoriasis reduce coronary inflammationOctober 8, 2019
Elnabawi YA, et al demonstrated that anti-inflammatory biologic therapies used to treat psoriasis can significantly reduce coronary inflammation in the patients. Scientists utilised a novel imaging biomarker, the perivascular fat attenuation index (FAI), to measure the effect of the therapy in reducing the inflammation. Perivascular FAI assessed coronary inflammation by mapping spatial changes of perivascular fat composition via coronary computed tomography angiography (CCTA).
The researchers analysed 134 patients who suffered from moderate to severe psoriasis. The participants underwent CT scans at the start of the study and again a year later to assess coronary inflammation using the perivascular FAI. Fifty-two of these patients who were treated with topical or light therapies alone served as the control group. The study reported a significant reduction in coronary inflammation among those receiving biologic therapy, but there was no change in the control group. Researchers suggest that the perivascular fat attenuation index may effectively help track response to interventions in coronary artery disease.
Source: JAMA Cardiology July 31, 2019 https://doi.org/10.1001/jamacardio.2019.2589